Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral InfectionMagnus J. Hansson, Matthew A. Gregory, Mohammad Nur‐e‐Alam et al.|Chemistry & Biology|2015Cited by 38
Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infectionSteven J. Moss, Matthew A. Gregory, Michael Bobardt et al.|MedChemComm|2011Cited by 26
P1044 NVP018, A CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HBV INFECTIONJ. Nilsson, Matthew A. Gregory, Steven J. Moss et al.|Journal of Hepatology|2014Cited by 8
841 BC556, A POTENT, PAN-GENOTYPIC, HIGH BARRIER TO RESISTANCE, SECOND GENERATION CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HCV INFECTIONSteven J. Moss, Matthew A. Gregory, Javier García-Rivera et al.|Journal of Hepatology|2012Cited by 2
789 PRECLINICAL CHARACTERIZATION OF NOVEL CYCLOPHILIN INHIBITORS BASED ON THE POLYKETIDE, SANGLIFEHRINSteven J. Moss, Matthew A. Gregory, Michael Bobardt et al.|Journal of Hepatology|2011Cited by 0